A clinico-molecular predictor identifies follicular lymphoma patients at risk of early transformation after first-line immunotherapy

Follicular lymphoma (FL) usually follows an indolent course and responds well to initial treatment. Overall survival (OS) has improved after the introduction of rituximab,[1][1] yet most patients experience multiple relapses and die from lymphoma. For some patients, relapses are associated with